The double upgrade is a notable contrarian signal, but the extreme price-to-consensus gap (70%+ downside to mean PT) and heavy insider selling suggest caution. Traders should wait for confirmation from price action or additional upgrades before taking a bullish position.
MRNA drugs
MRNA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 19 $174.38entry
- T+1 · 3mo ago −23.55%α −22.71% · $133.32
- T+5 · 3mo ago −14.18%α −13.79% · $149.66
- T+20 · 2mo ago −9.35%α −7.40% · $158.07
- T+60 · 5d ago +32.67%α +34.22% · $231.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
William Blair double-upgraded MRNA from Market Perform to Outperform on August 19, 2026, a rare two-step move that signals a significant shift in the firm's view. The upgrade comes as MRNA trades at $174.38, far above the consensus mean price target of $50.84, implying a 243% downside to the average target. The consensus is heavily bearish with 18 Holds, 2 Sells, and 1 Strong Sell versus only 9 Buy/Strong Buy ratings. William Blair has a 51% accuracy rate on 273 calls with a 4.2% average return, placing it in the middle tier among covering firms. Despite the bullish upgrade, the stock faces headwinds from a 60.1% short interest ratio and CEO Stephane Bancel selling $28.7 million in shares on August 5. EPS revisions over the past 30 days show a mixed picture: 7 upward revisions for the current quarter but 7 downward, while next quarter saw 11 upward and 3 downward. The bottom line: this is a contrarian call from a mid-accuracy firm against a deeply bearish consensus, but the extreme price-to-target gap and insider selling temper conviction.
Impact Score
Consensus & Targets
The consensus is heavily bearish: 2 Strong Buy, 7 Buy, 18 Hold, 2 Sell, 1 Strong Sell (30 analysts total). Only 30% of analysts are bullish (Buy/Strong Buy), while 10% are bearish (Sell/Strong Sell) and 60% are neutral. The consensus direction is decidedly cautious, with the majority on the sidelines.
Current price: $174.38. Consensus mean PT: $50.84, median: $45, high: $79, low: $25. Implied downside to mean: -70.8%. William Blair did not provide a price target, so its view cannot be directly compared to the consensus range. The stock trades at more than 3x the mean target, indicating extreme divergence between price and analyst expectations.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-19 | William Blair | upgrade | Outperform | No target |
| 2026-08-03 | Citigroup | maintain | Neutral | $60.00 |
| 2026-07-21 | Goldman Sachs | maintain | Neutral | No target |
| 2026-07-08 | Morgan Stanley | maintain | Equal-Weight | $39.00 |
| 2026-07-07 | RBC Capital | maintain | Sector Perform | $45.00 |
| 2026-07-07 | B of A Securities | maintain | Underperform | $38.00 |
| 2026-06-26 | Piper Sandler | maintain | Overweight | $77.00 |
| 2026-06-08 | B of A Securities | maintain | Underperform | $34.00 |
| 2026-05-04 | UBS | maintain | Neutral | No target |
| 2026-05-04 | Goldman Sachs | maintain | Neutral | $49.00 |
Over the past 30 days, there has been 1 upgrade (this one) and 0 downgrades. EPS revision trends show a mixed picture: for the current quarter, 7 upward revisions and 7 downward in the past 30 days, with the EPS estimate worsening from -$1.16 to -$1.35. For next quarter, 11 upward and 3 downward revisions, with the EPS estimate improving from -$2.01 to -$1.87. The current fiscal year estimate improved from -$8.66 to -$8.58 with 13 upward and 5 downward revisions. Overall, estimates are being revised slightly higher for near-term quarters but remain deeply negative.
Firm Track Record: William Blair
William Blair accuracy: 51% on 273 calls | avg return: 4.2%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 13 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Jefferies | 100% | 2/2 | 42.6% | top tier |
| Morgan Stanley | 75% | 3/4 | 26.9% | top tier |
| B of A Securities | 67% | 2/3 | 10% | top tier |
| Leerink Partners | 50% | 1/2 | 48.9% | below average |
| Citigroup | 50% | 1/2 | 31.7% | below average |
| JP Morgan | 50% | 3/6 | -7.9% | below average |
| RBC Capital | 38% | 3/8 | -7.9% | below average |
| Needham | 38% | 3/8 | -14.3% | below average |
| Barclays | 33% | 2/6 | -7.5% | below average |
| Piper Sandler | 25% | 1/4 | 4.5% | below average |
William Blair has a 51% accuracy rate on 273 calls with a 4.2% average return, placing it in the middle tier among covering firms. Among firms covering MRNA, the best performers are Jefferies (100% on 2 calls, 42.6% avg return), Morgan Stanley (75% on 4 calls, 26.9% avg return), and B of A Securities (67% on 3 calls, 10% avg return). The worst performers are Oppenheimer (0% on 2 calls, -41.8% avg return) and Evercore ISI (0% on 4 calls, -29.1% avg return). William Blair's track record is average relative to peers.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $-1.35 | $-3.32 to $-0.80 | $872.9M | ↑7 ↓0 |
| +1q | $-1.87 | $-2.31 to $-1.20 | $689.9M | ↑11 ↓0 |
| 0y | $-8.58 | $-10.55 to $-8.00 | $2.1B | ↑7 ↓0 |
| +1y | $-4.91 | $-7.11 to $-3.24 | $2.4B | ↑8 ↓0 |
Cross-Platform Signals
Insider trades show CEO Stephane Bancel sold $28.7 million in shares on August 5, 2026, and CFO Stephen Hoge sold $3.6 million on July 15. These are significant insider sales that oppose the bullish upgrade signal. Institutional activity is mixed: FIRST TRUST ADVISORS LP nearly exited (-99% position), while VICTORY CAPITAL MANAGEMENT doubled (+111.6%) and Clearstead Advisors added heavily (+731.2%). Short interest is extremely high at 60.1% of float, indicating heavy bearish positioning. No congressional trades were reported. The insider selling and high short interest diverge from the bullish analyst call, creating a conflicting signal.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
26 reports on MRNA
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers